


Amendments to the Claims

Please cancel Claims 1 and 4. Please amend Claim 2 and 5-8. The Claim Listing below will replace all prior versions of the Claims in the application:

Claim Listing

1. (Canceled)
2. (Currently amended) A pharmaceutical composition comprising a unit dosage form of a polydiallylamine homopolymer, said homopolymer characterized in that the polymer is free of alkylated amine monomers, and a pharmaceutically acceptable carrier. The pharmaceutical composition of Claim 1 wherein said homopolymer is crosslinked by means of a multifunctional crosslinking agent, and said crosslinking agent is present in an amount from about 2.5-20% by weight, based upon the combined weight of monomer and crosslinking agent.
3. (Previously presented) The pharmaceutical composition of Claim 2 wherein the polymer is crosslinked using epichlorohydrin.
4. (Canceled)
5. (Currently amended) A pharmaceutical composition comprising a unit dosage form of a polydiallylamine homopolymer, said homopolymer characterized in that the polymer is free of alkylated amine monomers, and a pharmaceutically acceptable carrier, wherein the polydiallylamine homopolymer is characterized by one or more monomeric units of the formulae:



or a combination thereof and salts thereof, The pharmaceutical composition of Claim 4
wherein the monomeric units are in the free-base form.

6. (Currently amended) The pharmaceutical composition of Claim [[4]] 5 wherein the monomeric units are a salt or a partial salt.
7. (Currently amended) [[A]] The pharmaceutical composition of Claim [[1]] 2 wherein the unit dosage form is a tablet.
8. (Currently amended) [[A]] The pharmaceutical composition of Claim [[1]] 2 wherein the unit dosage form is a capsule.